These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 31075204)
1. Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine. Zhao Z; Hu Y; Harmon T; Pentel P; Ehrich M; Zhang C Mol Pharm; 2019 Jun; 16(6):2766-2775. PubMed ID: 31075204 [TBL] [Abstract][Full Text] [Related]
2. Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction. Zhao Z; Harris B; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C Biomaterials; 2018 Feb; 155():165-175. PubMed ID: 29179132 [TBL] [Abstract][Full Text] [Related]
3. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density. Zhao Z; Powers K; Hu Y; Raleigh M; Pentel P; Zhang C Biomaterials; 2017 Apr; 123():107-117. PubMed ID: 28167389 [TBL] [Abstract][Full Text] [Related]
4. A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy. Zhao Z; Hu Y; Hoerle R; Devine M; Raleigh M; Pentel P; Zhang C Nanomedicine; 2017 Feb; 13(2):443-454. PubMed ID: 27520729 [TBL] [Abstract][Full Text] [Related]
5. Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine. Hu Y; Smith D; Zhao Z; Harmon T; Pentel PR; Ehrich M; Zhang C Nanomedicine; 2019 Aug; 20():102023. PubMed ID: 31181264 [TBL] [Abstract][Full Text] [Related]
6. Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins. Zhao Z; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C Nanomedicine; 2018 Jul; 14(5):1655-1665. PubMed ID: 29719216 [TBL] [Abstract][Full Text] [Related]
7. Toll-like Receptor 9 Agonists as Adjuvants for Nanoparticle-Based Nicotine Vaccine. Hu Y; Smith D; Frazier E; Zhao Z; Zhang C Mol Pharm; 2021 Mar; 18(3):1293-1304. PubMed ID: 33497574 [TBL] [Abstract][Full Text] [Related]
8. Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization. Zhao Z; Hu Y; Harmon T; Pentel P; Ehrich M; Zhang C Biomaterials; 2017 Sep; 138():46-56. PubMed ID: 28551462 [TBL] [Abstract][Full Text] [Related]
9. Development of nanoparticle adjuvants to potentiate the immune response against diphtheria toxoid. Alshanqiti FM; Al-Masaudi SB; Al-Hejin AM; El-Baky NA; Redwan EM Hum Antibodies; 2018 Feb; 26(2):75-85. PubMed ID: 29171990 [TBL] [Abstract][Full Text] [Related]
10. Paradox of PEGylation in fabricating hybrid nanoparticle-based nicotine vaccines. Hu Y; Zhao Z; Harmon T; Pentel PR; Ehrich M; Zhang C Biomaterials; 2018 Nov; 182():72-81. PubMed ID: 30107271 [TBL] [Abstract][Full Text] [Related]
11. Formulation of Nanovaccines toward an Extended Immunity against Nicotine. Hu Y; Zhao Z; Ehrich M; Zhang C ACS Appl Mater Interfaces; 2021 Jun; 13(24):27972-27982. PubMed ID: 34105952 [TBL] [Abstract][Full Text] [Related]
12. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. McCluskie MJ; Pryde DC; Gervais DP; Stead DR; Zhang N; Benoit M; Robertson K; Kim IJ; Tharmanathan T; Merson JR; Davis HL Int Immunopharmacol; 2013 May; 16(1):50-6. PubMed ID: 23562759 [TBL] [Abstract][Full Text] [Related]
13. A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle. Hu Y; Zheng H; Huang W; Zhang C Hum Vaccin Immunother; 2014; 10(1):64-72. PubMed ID: 24091786 [TBL] [Abstract][Full Text] [Related]
14. The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine. Hu Y; Smith D; Frazier E; Hoerle R; Ehrich M; Zhang C Biomaterials; 2016 Nov; 106():228-39. PubMed ID: 27569868 [TBL] [Abstract][Full Text] [Related]
15. Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles. Kabiri M; Sankian M; Sadri K; Tafaghodi M Eur J Pharm Biopharm; 2018 Dec; 133():321-330. PubMed ID: 30408519 [TBL] [Abstract][Full Text] [Related]
16. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929 [TBL] [Abstract][Full Text] [Related]
17. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. Pryde DC; Jones LH; Gervais DP; Stead DR; Blakemore DC; Selby MD; Brown AD; Coe JW; Badland M; Beal DM; Glen R; Wharton Y; Miller GJ; White P; Zhang N; Benoit M; Robertson K; Merson JR; Davis HL; McCluskie MJ PLoS One; 2013; 8(10):e76557. PubMed ID: 24098532 [TBL] [Abstract][Full Text] [Related]
18. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Zhang W; Wang L; Liu Y; Chen X; Liu Q; Jia J; Yang T; Qiu S; Ma G Biomaterials; 2014 Jul; 35(23):6086-97. PubMed ID: 24780166 [TBL] [Abstract][Full Text] [Related]
19. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Chen X; Pravetoni M; Bhayana B; Pentel PR; Wu MX Vaccine; 2012 Dec; 31(1):159-64. PubMed ID: 23123021 [TBL] [Abstract][Full Text] [Related]
20. Squalene containing solid lipid nanoparticles, a promising adjuvant system for yeast vaccines. Stelzner JJ; Behrens M; Behrens SE; Mäder K Vaccine; 2018 Apr; 36(17):2314-2320. PubMed ID: 29567034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]